Actively Recruiting
Intervention of Nicotinamide Mononucleotide in Middle-aged and Elderly People
Led by People's Hospital of Quzhou · Updated on 2026-05-08
240
Participants Needed
1
Research Sites
175 weeks
Total Duration
On this page
Sponsors
P
People's Hospital of Quzhou
Lead Sponsor
B
Beijing Institute of Genomics, Chinese Academy of Sciences
Collaborating Sponsor
AI-Summary
What this Trial Is About
This study is a single-center, randomized, double-blind, placebo-controlled clinical trial investigating a pharmacological intervention for aging. Its primary objective is to evaluate the efficacy of NMN while ensuring the safety of oral administration, with the aim of identifying effective strategies to delay aging and improve the quality of life in the elderly population. The main outcomes of this study are to characterize the patterns of NMN efficacy across different populations and to identify sensitive biomarkers that reflect responsiveness to the intervention.
CONDITIONS
Official Title
Intervention of Nicotinamide Mononucleotide in Middle-aged and Elderly People
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Local residents of Quzhou or living in Quzhou for over ten years
- Age 40 to 50 years or 60 to 70 years
- Any gender
- In good health and no major surgery within the past six months
- Able to communicate well with researchers and cooperate during the study
- Able to voluntarily sign written informed consent
You will not qualify if you...
- Alcoholism, heavy smoking (more than 5 packs/day, 20 cigarettes per pack), drug or substance abuse
- Participation in other clinical trials or use of research drugs or equipment within 30 days before enrollment
- Obesity with BMI over 30
- Pregnant or breastfeeding women
- History of any cancer (except basal cell or squamous cell skin cancer)
- History of coronary artery disease, myocardial infarction, or significant heart failure (if under 60)
- History of stroke or transient ischemic attack (if under 60)
- History of deep vein thrombosis or pulmonary embolism (if under 60)
- Serum creatinine over 1.5 mg/dl (if male and under 60)
- Poorly controlled hypertension (systolic >160 mmHg or diastolic >100 mmHg)
- History of active liver disease or metabolic acidosis
- Chronic kidney disease, hemodialysis treatment, severe kidney damage, or EGFR ≤ 45 ml/min/1.73m2
- Severe autoimmune or inflammatory diseases such as rheumatoid arthritis, lupus, Crohn's disease
- Nervous system diseases like dementia, Alzheimer’s or Parkinson’s disease
- Diabetes mellitus with hemoglobin >6.5%, fasting blood glucose >126 mg/dL, or on diabetes medication
- Recent cardiovascular events within 3 months
- Infectious diseases such as HIV, hepatitis, tuberculosis
- Hand or lower limb disability affecting normal function and life
- Regular use of chemotherapy drugs, antiplatelet drugs (except aspirin), or cholinesterase inhibitors for Alzheimer’s disease
- Any physical condition that may adversely impact the research or results
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
People's Hospital of Quzhou
Quzhou, Zhejiang, China, 324000
Actively Recruiting
Research Team
F
Feng Zhang
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
BASIC_SCIENCE
Number of Arms
8
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here